Clinical trial • Not applicable • Neurology
Botulinum toxin type A - haemagglutinin complex for Dystonic tremor syndrome
Not applicable trial of Botulinum toxin type A - haemagglutinin complex for Dystonic tremor syndrome. 60 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Dystonic tremor syndrome
- Trial Stage
- Not applicable
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 14-08-2024
- First CTIS Authorization Date
- 11-11-2024
Trial design
Not applicable trial across 3 sites in Netherlands.
- Target Sample Size
- 60
Eligibility
Recruits 60 No vulnerable population selected; only adults (Age ≥ 18 years). Subject information and informed consent form for adults available (L1_SIS and ICF adults public)..
- Pregnancy Exclusion
- Pregnancy, trying to conceive and breastfeeding
- Vulnerable Population
- No vulnerable population selected; only adults (Age ≥ 18 years). Subject information and informed consent form for adults available (L1_SIS and ICF adults public).
Inclusion criteria
- {"criterion_text":"- Clinical diagnosis of dystonic tremor or tremor associated with dystonia according to the 2018 consensus statement on the classification of tremors"}
- {"criterion_text":"- Tremor of one or both upper extremities"}
- {"criterion_text":"- Starting botulinum neurotoxin injections as part of normal clinical practice"}
- {"criterion_text":"- Age ≥ 18 years"}
Exclusion criteria
- {"criterion_text":"- Acquired aetiology of dystonic tremor syndrome"}
- {"criterion_text":"- Previous botulinum neurotoxin treatment of the to be treated upper extremity for ≥ 4 consecutive sessions"}
- {"criterion_text":"- In case of previous botulinum neurotoxin treatment of the to be treated upper extremity for ≤3 consecutive sessions: the last botulinum neurotoxin injections ≤ 6 months before study enrolment"}
- {"criterion_text":"- Unstable dose medications for dystonia and tremor ≤ 1 month before study enrolment"}
- {"criterion_text":"- Deep brain stimulation implantation ≤ 6 months before study enrolment"}
- {"criterion_text":"- Unstable deep brain stimulation variables ≤ 1 month before study enrolment"}
- {"criterion_text":"- Comorbidity interfering with study participation"}
- {"criterion_text":"- Known hypersensitivity for components of Dysport"}
- {"criterion_text":"- Infection at the upper extremity"}
- {"criterion_text":"- Pregnancy, trying to conceive and breastfeeding"}
- {"criterion_text":"- Insufficient knowledge of the Dutch or English language"}
Endpoints
Primary endpoints
- {"endpoint_text":"- The associations between clinical (e.g. dystonic tremor versus tremor associated with dystonia, jerkiness, dominant tremor pattern, sensory trick), electrophysiological (e.g. frequency-width at half-width power, intermuscular coherence), ultrasonographic (e.g. echogenicity, muscle thickness, tremulous muscles) and (functional) magnetic resonance imaging tremor characteristics (e.g. ratio of tremor-related activity in the basal ganglia versus cerebello-thalamo-cortical circuit)","definition_or_measurement_approach":"Associations assessed across clinical assessments (phenotype features such as jerkiness, dominant tremor pattern, sensory trick), electrophysiological measures (e.g. frequency-width at half-width power, intermuscular coherence), ultrasonographic measures (echogenicity, muscle thickness, identification of tremulous muscles) and (functional) MRI measures (e.g. ratio of tremor-related activity in basal ganglia vs cerebello-thalamo-cortical circuit) in relation to botulinum neurotoxin efficacy."}
Secondary endpoints
- {"endpoint_text":"- The clinical, electrophysiological, ultrasonographic and (functional) magnetic resonance imaging differences between dystonic tremor and tremor associated with dystonia at baseline (e.g. jerkiness, dominant tremor pattern, frequency-width at half-width power, intermuscular coherence, tremulous muscles, ratio of tremor-related activity in the basal ganglia versus cerebello-thalamo-cortical circuit).","definition_or_measurement_approach":"Baseline comparisons using clinical assessments, electrophysiological measures (frequency-width at half-width power, intermuscular coherence), ultrasonography (tremulous muscles) and (f)MRI (ratio of tremor-related activity) between dystonic tremor and tremor associated with dystonia."}
- {"endpoint_text":"- The agreement between a clinical assessment, polymyography and muscle ultrasound on muscle selection","definition_or_measurement_approach":"Agreement analysis between clinical muscle selection, polymyography results and muscle ultrasound findings for selection of muscles to treat."}
Recruitment
- Planned Sample Size
- 60
- Recruitment Window Months
- 29
- Consent Approach
- Informed consent is required from adult participants (Age ≥ 18 years). A subject information sheet and informed consent form for adults is listed (L1_SIS and ICF adults public). No assent procedures described.
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 60
Netherlands
- Earliest CTIS Part Ii Submission Date
- 27-08-2024
- Latest Decision Or Authorization Date
- 11-11-2024
- Processing Time Days
- 76
- Number Of Sites
- 3
- Number Of Participants
- 60
Sites
- Site Name
- Canisius Wilhelmina Ziekenhuis
- Department Name
- Neurology
- Contact Person Name
- Frouke Nijhuis
- Contact Person Email
- f.nijhuis@cwz.nl
- Site Name
- Radboud universitair medisch centrum / RADBOUDUMC
- Department Name
- Neurology
- Contact Person Name
- Anke Snijders
- Contact Person Email
- anke.snijders@radboudumc.nl
- Site Name
- Radboud Universiteit Nijmegen
- Department Name
- Donders Centre for Cognitive Neuroimaging
- Contact Person Name
- Rick Helmich
- Contact Person Email
- rick.helmich@radboudumc.nl
Sponsor
Primary sponsor
- Full Name
- Stichting Radboud universitair medisch centrum
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Third parties
- {"country":"","full_name":"Radboud University Medical Centre","duties_or_roles":"Source of monetary support","organisation_type":""}
- {"country":"","full_name":"Canisius-Wilhelmina Hospital","duties_or_roles":"Source of monetary support","organisation_type":""}
Investigational products
- Investigational Product Name
- Dysport 300 E, poeder voor oplossing voor injectie
- Active Substance
- Botulinum toxin type A - haemagglutinin complex
- Modality
- Peptide/protein/enzyme
- Routes Of Administration
- INJECTION
- Route
- INJECTION
- Authorisation Status
- Authorised (marketing authorisation RVG 110868, NL)
- Maximum Dose
- 1000 U unit(s)
Related trials
Other published trials that may interest you.
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease
- Tenecteplase for Acute ischaemic stroke due to basilar artery occlusion | Posterior circulation ischaemic stroke